Sequent Scientific Limited (SEQUENT.BO)
INR 136.85
(8.18%)
INR 136.85
(8.18%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -358.69 Million INR | 70.4% |
| 2022 | -1.21 Billion INR | -395.83% |
| 2021 | 409.55 Million INR | -57.09% |
| 2020 | 954.42 Million INR | 36.53% |
| 2019 | 699.05 Million INR | 43.66% |
| 2018 | 486.6 Million INR | -88.46% |
| 2017 | 4.21 Billion INR | 3149.52% |
| 2016 | -138.24 Million INR | 25.15% |
| 2015 | -184.69 Million INR | -72.01% |
| 2014 | -107.37 Million INR | 90.28% |
| 2013 | -1.1 Billion INR | -70.79% |
| 2012 | -646.94 Million INR | -4524.3% |
| 2011 | -13.99 Million INR | -694.89% |
| 2010 | -1.76 Million INR | -100.47% |
| 2009 | 374.17 Million INR | 355.25% |
| 2008 | -146.59 Million INR | -681.28% |
| 2007 | 25.21 Million INR | -70.59% |
| 2006 | 85.75 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 65.1 Million INR | 814.6% |
| 2023 FY | -358.69 Million INR | 70.4% |
| 2023 Q1 | -348.46 Million INR | 62.76% |
| 2023 Q2 | -83.8 Million INR | 75.95% |
| 2023 Q3 | 82.68 Million INR | 198.66% |
| 2023 Q4 | -9.11 Million INR | -111.02% |
| 2022 Q2 | -37.5 Million INR | 74.94% |
| 2022 Q3 | -88.69 Million INR | -136.51% |
| 2022 FY | -1.21 Billion INR | -395.83% |
| 2022 Q4 | -935.74 Million INR | -955.07% |
| 2022 Q1 | -149.66 Million INR | -266.99% |
| 2021 Q4 | 89.62 Million INR | -47.64% |
| 2021 Q2 | 143 Million INR | 1538.03% |
| 2021 FY | 409.55 Million INR | -57.09% |
| 2021 Q3 | 171.16 Million INR | 19.69% |
| 2021 Q1 | 8.73 Million INR | -94.56% |
| 2020 FY | 954.42 Million INR | 36.53% |
| 2020 Q4 | 160.36 Million INR | -54.85% |
| 2020 Q3 | 355.16 Million INR | 51.19% |
| 2020 Q2 | 234.91 Million INR | 48.67% |
| 2020 Q1 | 158.01 Million INR | -6.25% |
| 2019 Q3 | 203.05 Million INR | -4.62% |
| 2019 Q2 | 212.88 Million INR | 85.81% |
| 2019 Q1 | 114.57 Million INR | -33.09% |
| 2019 Q4 | 168.55 Million INR | -16.99% |
| 2019 FY | 699.05 Million INR | 43.66% |
| 2018 Q1 | 32.8 Million INR | -99.18% |
| 2018 Q4 | 171.24 Million INR | 31.47% |
| 2018 Q3 | 130.25 Million INR | -14.48% |
| 2018 Q2 | 152.31 Million INR | 364.36% |
| 2018 FY | 486.6 Million INR | -88.46% |
| 2017 Q2 | 292.39 Million INR | 1207.07% |
| 2017 FY | 4.21 Billion INR | 3149.52% |
| 2017 Q1 | 22.37 Million INR | -67.21% |
| 2017 Q3 | -94.59 Million INR | -132.35% |
| 2017 Q4 | 4.01 Billion INR | 4343.32% |
| 2016 Q4 | 68.22 Million INR | 230.06% |
| 2016 Q2 | -51.52 Million INR | 49.73% |
| 2016 FY | -138.24 Million INR | 25.15% |
| 2016 Q1 | -102.49 Million INR | 26.6% |
| 2016 Q3 | -52.45 Million INR | -1.81% |
| 2015 Q1 | 466 Thousand INR | 100.22% |
| 2015 FY | -184.69 Million INR | -72.01% |
| 2015 Q4 | -139.62 Million INR | -24.07% |
| 2015 Q3 | -112.53 Million INR | -310.25% |
| 2015 Q2 | 53.52 Million INR | 11386.05% |
| 2014 FY | -107.37 Million INR | 90.28% |
| 2014 Q4 | -216.1 Million INR | -91.6% |
| 2014 Q3 | -112.78 Million INR | -133.6% |
| 2014 Q2 | 335.63 Million INR | 394.11% |
| 2014 Q1 | -114.11 Million INR | 85.5% |
| 2013 Q3 | -150.66 Million INR | -105.37% |
| 2013 Q1 | -94.02 Million INR | 72.39% |
| 2013 Q4 | -786.88 Million INR | -422.27% |
| 2013 FY | -1.1 Billion INR | -70.79% |
| 2013 Q2 | -73.36 Million INR | 21.98% |
| 2012 Q2 | -41.81 Million INR | 72.46% |
| 2012 FY | -646.94 Million INR | -4524.3% |
| 2012 Q1 | -151.8 Million INR | 0.0% |
| 2012 Q3 | -112.78 Million INR | -169.74% |
| 2012 Q4 | -340.55 Million INR | -201.96% |
| 2011 FY | -13.99 Million INR | -694.89% |
| 2010 FY | -1.76 Million INR | -100.47% |
| 2009 FY | 374.17 Million INR | 355.25% |
| 2008 FY | -146.59 Million INR | -681.28% |
| 2007 FY | 25.21 Million INR | -70.59% |
| 2006 FY | 85.75 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 105.825% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 101.13% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 107.617% |
| Granules India Limited | 4.05 Billion INR | 108.85% |
| Indoco Remedies Limited | 984.6 Million INR | 136.43% |
| Achyut Healthcare Limited | 5.73 Million INR | 6357.676% |
| Ajanta Pharma Limited | 8.16 Billion INR | 104.395% |
| Alkem Laboratories Limited | 17.95 Billion INR | 101.997% |
| Alpa Laboratories Limited | 167.76 Million INR | 313.805% |
| Brooks Laboratories Limited | -195.91 Million INR | -83.081% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 122.209% |
| Bajaj HealthCare Limited | -837.93 Million INR | 57.193% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 147.538% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 100.644% |
| Eris Lifesciences Limited | 3.91 Billion INR | 109.151% |
| FDC Limited | 3.05 Billion INR | 111.752% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 97.611% |
| Gufic Biosciences Limited | 861.35 Million INR | 141.642% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 108.521% |
| Ipca Laboratories Limited | 5.47 Billion INR | 106.553% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 259.68% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | -81.814% |
| Lasa Supergenerics Limited | -217.3 Million INR | -65.062% |
| Laurus Labs Limited | 1.6 Billion INR | 122.341% |
| Lupin Limited | 19.14 Billion INR | 101.874% |
| Mankind Pharma Limited | 19.12 Billion INR | 101.875% |
| Medicamen Biotech Limited | 109.31 Million INR | 428.14% |
| Medico Remedies Limited | 82.9 Million INR | 532.631% |
| Megasoft Limited | -127.46 Million INR | -181.401% |
| NATCO Pharma Limited | 13.88 Billion INR | 102.584% |
| Piramal Pharma Limited | 178.2 Million INR | 301.285% |
| RPG Life Sciences Limited | 876.6 Million INR | 140.918% |
| Sigachi Industries Limited | 571.8 Million INR | 162.73% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 100.375% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 111.945% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 241.695% |
| Unichem Laboratories Limited | -704.74 Million INR | 49.103% |
| Wanbury Limited | 559.56 Million INR | 164.102% |
| Windlas Biotech Limited | 581.87 Million INR | 161.644% |
| ZIM Laboratories Limited | 172.46 Million INR | 307.98% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 100.929% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 90.737% |
| Divi's Laboratories Limited | 16 Billion INR | 102.242% |
| Hester Biosciences Limited | 188.89 Million INR | 289.894% |
| Procter & Gamble Health Limited | 2 Billion INR | 117.847% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 179.757% |
| Bal Pharma Limited | 73.92 Million INR | 585.228% |
| Strides Pharma Science Limited | -706.14 Million INR | 49.204% |
| Venus Remedies Limited | 284.9 Million INR | 225.897% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 116.537% |
| Nectar Lifesciences Limited | 49.95 Million INR | 818.098% |
| Shilpa Medicare Limited | 318.74 Million INR | 212.533% |
| Aarti Drugs Limited | 1.71 Billion INR | 120.925% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 126.682% |
| Suven Life Sciences Limited | -1.05 Billion INR | 65.864% |
| Ind-Swift Limited | 142.31 Million INR | 352.043% |
| Valiant Laboratories Limited | 3.19 Million INR | 11323.091% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 106.491% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 93.678% |
| Themis Medicare Limited | 435.23 Million INR | 182.412% |
| Hikal Limited | 696.02 Million INR | 151.534% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 102.166% |
| Novartis India Limited | 851.9 Million INR | 142.105% |
| Wockhardt Limited | -4.63 Billion INR | 92.253% |
| Jubilant Pharmova Limited | 771 Million INR | 146.523% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | 5157.671% |
| Neuland Laboratories Limited | 3 Billion INR | 111.953% |
| Morepen Laboratories Limited | 961.59 Million INR | 137.301% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 345.655% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | -295.394% |